Numinus to Participate in AAAS 2022 Annual Meeting on February 17-20, 2022

Dr. Devon Christie, Dr. Robin Carhart-Harris, Dr. Frederick Barrett and Tura Patterson will discuss “Psychedelic Research: Moving Beyond the Social and Political Stigma”

VANCOUVER, BC, Feb. 10, 2022 – Numinus Wellness Inc. (TSX:NUMI)(OTCPK:LKYSF)(“Numinus” or the “Company”) a mental healthcare company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that it will participate in the American Association for the Advancement of Science (AAAS) 2022 Annual Meeting, hosted virtually February 17-20, 2022.

Dr. Devon Christie, Senior Lead Psychedelic Programs of Numinus Wellness Inc. (TSX:NUMI)(OTCPK:LKYSF), will join Dr. Robin Carhart-Harris (Imperial College London) and Dr. Frederick Barrett (Johns Hopkins University) for a Scientific Session on “Psychedelic Research: Moving Beyond the Social and Political Stigma”, moderated by Tura Patterson (Usona Institute) on Saturday, February 19, 2022, at 3:00 p.m. ET. This session is open to registered attendees with Deluxe Access.

Dr. Christie, Dr. Barrett and Ms. Patterson will also convene for Media Availability on Sunday, February 20, 2022, at 9:00 a.m. ET. This session is open to registered media only, with complementary registration.

For general information about the event, please visit meetings.aaas.org or contact [email protected]; for media information, please visit https://meetings.aaas.org/wp-content/uploads/AM22_MA-grids_final.pdf. For information about Numinus Wellness Inc.’s (TSX:NUMI)(OTCPK:LKYSF) participation, please contact [email protected].

About Numinus

Numinus Wellness Inc. (TSX:NUMI)(OTCPK:LKYSF) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus Wellness Inc. (TSX:NUMI)(OTCPK:LKYSF) model – including psychedelic production, research, and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus Wellness Inc. (TSX:NUMI)(OTCPK:LKYSF), we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.

Learn more at numinus.com and follow us on LinkedIn, Facebook, Twitter, and Instagram.

Forward-Looking Statements

Statements and other information contained in this press release about anticipated future events constitute forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect” and “intend” and statements that an event “may”, “will”, “should”, “could” or “might” occur or other similar expressions. Forward-looking statements are subject to risks and uncertainties and other factors that could cause actual results to differ materially from those contained in the forward-looking statements. Forward-looking statements are based on estimates and opinions of management at the date the statements are made. The Company does not undertake any obligation to update forward-looking statements even if circumstances or management’s estimates or opinions should change except as required by applicable laws. Investors should not place undue reliance on forward-looking statements.

SOURCE Numinus Wellness Inc. (TSX:NUMI)(OTCPK:LKYSF)